PAPPA and invasive breast carcinoma: Recombinant IGFBP4, capable of IGF-1 binding and resistant to protease cleavage by pregnancy-associated plasma protein-A (PAPP-A), has been shown to block mammary tumor growth and inhibit angiogenesis in a murine BrCa model [69].